Understanding the R&D landscape
2 likes308 views
The document discusses the current state of research and development funding for vaccines targeting HIV and tuberculosis, emphasizing that funding is heavily concentrated among a few major organizations. It highlights a decline in overall funding for neglected diseases and stresses the need for reliable, outcome-driven funding to support the promising advancements in vaccine development. Key messages advocate for smarter, coordinated, and flexible funding strategies to maximize health impacts in tackling these diseases.
Understanding the R&D landscape
- 1. The Power of Vaccines: getting to zero for HIV and TB Understanding the R&D funding landscape Roni Liyanage Senior Policy Analyst rliyanage@policycures.org
- 2. Outline About Policy Cures About G-FINDER Neglected disease R&D funding Vaccine R&D funding HIV & TB vaccine funding Key messages
- 3. About Policy Cures Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the developing world
- 4. About G-FINDER An annual funding survey (2007, 2008, 2009, 2010) 31 neglected diseases 134 product areas All R&D stages Over 8,000 entries per year Data from 54 countries <INSERT PICTURE> Data from 240 organisations Funded by the Bill & Melinda Gates Foundation WHO/MALI
- 5. Neglected Disease R&D Funding
- 6. Total Neglected Disease R&D funding $3,500 Millions $3,000 $2,500 $3,063 $2,000 million $1,500 invested in neglected disease R&D in 2010 $1,000 $500 $109m (-3.5%) $0 2007 2008 2009 2010
- 7. HIV & TB R&D funding $1,200 Millions HIV/AIDS TB $1,000 $800 $600 HIV $1.07 TB $575.4 BILLION $400 MILLION Total spend on Total spend on TB R&D HIV/AIDS R&D in 2010 in 2010 $200 35% 18.8% of Global ND R&D $- of Global ND R&D funding 2007 2008 2009 2010 funding
- 9. Vaccine R&D funding $1,400 Millions $1,200 62% Public funding $1,000 $800 $600 20% $400 Industry funding $200 $0 2007 2008 2009 2010 17% Public funding Industry funding Philanthropic funding Philanthropic funding
- 10. Vaccine R&D funding Bacterial Other 4% Pneumonia & Meningitis 7% Diarrhoeal diseases 7% Malaria 8% HIV/AIDS 55% TB 9% Dengue 10%
- 11. Top funders of neglected disease vaccine R&D, 2010 1 NIH $509m 2 Pharmaceutical Industry $223m 3 Bill & Melinda Gates Foundation $176m 4 US Department of Defense (DOD) $43m 5 US Agency for International Development (USAID) $33m 6 UK Department for International Development (DFID) $30m 7 European Commission: Research Directorate-General $27m
- 12. HIV & TB Vaccine R&D Funding
- 13. HIV & TB Vaccine R&D funding 2007-2010 $700 Millions HIV/AIDS TB $600 $500 $400 HIV $589.9 $300 TB $81.9 million $200 MILLION Total spend on HIV Total spend on TB Vaccine R&D in 2010 $100 Vaccine R&D in 2010 $- 2007 2008 2009 2010
- 14. HIV Vaccine R&D funding by funder type 2010 Industry Philanthropic funding funding 2% Top funders HIV Vaccine R&D, 2010 12% 1 US NIH $414m 2 Bill & Melinda Gates $65m Foundation 3 USAID $27m 4 US DoD $25m 5 Industry $21m 6 UK DFID $14m Public 7 European Commission $10m funding 86% 8 The Wellcome Trust $4m
- 15. TB Vaccine R&D funding by funder type, 2010 Other Industry 2% Top funders TB Vaccine R&D, 2010 funding 1 Bill & Melinda Gates Foundation $30m 9% Public funding 49% 2 Industry $17m 3 US NIH $15m 4 UK DFID $10m 5 Health Protection Agency $4m 6 European Commission $4m Philanthropic funding 40%
- 16. Science & Technology Vs Aid funding 90% of public funding for HIV vaccine R&D came from Science and Technology funding agencies in 2010 66% of public funding for TB vaccine R&D came from Science and Technology funding agencies in 2010
- 17. European public funding of HIV Vaccine R&D $70 Millions $60 $15.8m (-29%) in 2010 Norway $50 Switzerland France $40 Sweden Denmark $16.7m (-22%) in 2010 $30 From UK Ireland Netherlands $20 European Commission UK $10 $10.8m (-36%) in 2010 $- From EC 2007 2008 2009 2010
- 18. European public funding of TB Vaccine R&D $35 Millions $30 $5.9m (-20%) in 2010 $25 Spain Sweden $20 Denmark Switzerland $14.3m (up 21%) in 2010 $15 From UK Netherlands European Commission $10 UK $5 $4.0m (-45%) in 2010 From EC $- 2007 2008 2009 2010
- 19. The HIV and TB vaccine portfolios 30 25 20 Preclinical Several products moving 15 Phase I into expensive late-stage Phase II clinical trials 10 Phase III 5 0 HIV Vaccines TB Vaccine
- 20. Key messages
- 21. Vaccine R&D funding for neglected diseases Funding is highly concentrated Mostly comes from: US funders Public sector Science and technology budgets Funding cuts at a time when several promising products are entering late stage development
- 22. Vaccine R&D funding for neglected diseases - R&D pipelines need reliable long-term funding - Financial pressures mean smarter funding will be needed: - Outcome driven and flexible - Aligned with product and portfolio developments - Coordinated - Targeted to deliver the highest health impact
- 23. It took a long time and a lot of effort to restart neglected disease vaccine R&D but it is under threat The time to act is NOW